All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lupus content recommended for you
.jpg)
Important announcement
Read more 👉 https://loom.ly/BZDFTTg
More drug updates
VIEW ALL
Obinutuzumab receives U.S. FDA approval for the treatment of lupus nephritis
@US_FDA approves obinutuzumab for the treatment of adult patients with active #LupusNephritis, who are receiving standard therapy, as well as a shorter 90-minute infusion time after the first infusion, for eligible patients. Read more: loom.ly/EXKLaUA
.jpg&w=3840&q=75)